Helius Therapeutics has been granted GMP certification to manufacture medicines containing THC by MedSafe.
According to industry sources, Helius could have locally made THC products available in New Zealand within weeks. The approval also meets EU-GMP standards, opening up future export opportunities.
Last week, the firm announced it had received Good Agricultural and Collection Practice (GACP) certification for its medicinal cannabis facility in East Auckland.
Chief executive Carmen Doran said the milestones “allow us to bring more NZ-grown and made products to Kiwi patients”.
She added: “The GMP certification process has been exhaustive, and rightly so. We’re making medicines, so there is no room for cutting corners.
“Helius pulled together an internationally-experienced leadership team from both the pharmaceutical and medicinal cannabis industries to successfully achieve this level of compliance.
“[We have] built the team and facilities to get the job done, motivated by an unwavering commitment to improve patients’ quality of life.”
